Laboratorios Farmaceuticos Rovi, S.A. (FRA:41L)

Market Cap	3.06B
Revenue (ttm)	724.20M
Net Income (ttm)	121.15M
Shares Out	n/a
EPS (ttm)	2.37
PE Ratio	25.27
Forward PE	20.65
Dividend	0.76 (1.26%)
Ex-Dividend Date	Jul 14, 2025

Volume	n/a
Average Volume	16
Open	60.05
Previous Close	59.95
Day's Range	60.05 - 60.05
52-Week Range	46.30 - 65.90
Beta	n/a
RSI	54.85
Earnings Date	Feb 23, 2026

About FRA:41L

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,...

• Industry: Pharmaceutical Preparations
• Founded: 1946
• Employees: 2,197
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 41L

Financial Performance

In 2024, FRA:41L's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.